-+ 0.00%
-+ 0.00%
-+ 0.00%

Minerva Neurosciences forms scientific advisory board for roluperidone program

PUBT·06/01/2026 20:05:33
Listen to the news
Minerva Neurosciences forms scientific advisory board for roluperidone program
  • Minerva Neurosciences formed a Scientific Advisory Board to guide the Phase 3 confirmatory trial of roluperidone and broader R&D strategy.
  • Chief Medical Officer Michael Davidson joined the board alongside CEO Remy Luthringer.
  • New members include University of Miami psychiatry professor Philip Harvey, King’s College London molecular psychiatry professor Oliver Howes, Draig Therapeutics CMO Inder Kaul.
  • Additional appointees include University of Arkansas psychiatry professor Brian Kirkpatrick, Mount Sinai psychiatry and preventive medicine professor Avi Reichenberg, University of Georgia professor Greg Strauss.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606011605OMX_____CNEWS_EN_GNW9729098_en) on June 01, 2026, and is solely responsible for the information contained therein.